Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Nevala-Plagemann C, Francis S, Cavalieri C, et al. Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open. 2018;3(5):e000386.
   PubMed Web of Science ®Google Scholar
• Papaxoinis G, Kamposioras K, Weaver JMJ, et al. The role of continuing perioperative chemotherapy post surgery in patients with esophageal or gastroesophageal junction adenocarcinoma: a multicenter cohort study. J Gastrointest Surg. 2019;23(9):1729–1741.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
   PubMed Web of Science ®Google Scholar
• Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062–5067.
   PubMed Web of Science ®Google Scholar
• van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084.
   PubMed Web of Science ®Google Scholar
• Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–1098.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO. Lancet Oncol. 2016;17(12):1697–1708.
   PubMed Web of Science ®Google Scholar
• Hoeppner J, Lordick F, Brunner T, et al. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer. 2016;16:503.
   PubMed Web of Science ®Google Scholar
• Reynolds JV, Preston SR, O'Neill B, et al. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction international study (Neo-AEGIS). BMC Cancer. 2017;17(1):401.
   PubMed Web of Science ®Google Scholar
• Drake J, Tauer K, Portnoy D, et al. Adjuvant chemotherapy is associated with improved survival in patients with nodal metastases after neoadjuvant therapy and esophagectomy. J Thorac Dis. 2019;11(6):2546–2554.
   PubMed Web of Science ®Google Scholar
• Greally M, Ku GY. Adjuvant chemotherapy for poor pathologic response after pre-operative chemoradiation in esophageal cancer: infeasible and illogical. J Thorac Dis. 2019;11(15):S1855–S1860.
   PubMed Web of Science ®Google Scholar
• Saunders JH, Bowman CR, Reece-Smith AM, et al. The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery. J Surg Oncol. 2017;115(7):821–829.
   PubMed Web of Science ®Google Scholar
• The Royal College of Pathologists. Dataset for the histopathological reporting of oesophageal carcinoma (2nd edition). Document G006. 2007. Available from: https://www.rcpath.org/uploads/assets/f8b1ea3d-5529-4f85-984c8d4d8556e0b7/068e9093-0aea-4316-bdd49771564784b9/g006-dataset-for-histopathological-reporting-of-oesophageal-and-gastric-carcinoma.pdf
   Google Scholar
• Mandard AM, Dalibard F, Mandard J, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathol Correlat Cancer. 1994;73(11):2680–2686.
   Google Scholar
• Davies AR, Myoteri D, Zylstra J, et al. Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma. Br J Surg. 2018;105(12):1639–1649.
   PubMed Web of Science ®Google Scholar
• Davies AR, Gossage JA, Zylstra J, et al. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol. 2014;32(27):2983–2990.
   PubMed Web of Science ®Google Scholar
• Burt BM, Groth SS, Sada YH, et al. Utility of adjuvant chemotherapy after neoadjuvant chemoradiation and esophagectomy for esophageal cancer. Ann Surg. 2017;266(2):297–304.
   PubMed Web of Science ®Google Scholar
• Glatz T, Bronsert P, Schäfer M, et al. Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: postoperative chemotherapy has a substantial impact on outcome. Eur J Surg Oncol. 2015;41(10):1300–1307.
   PubMed Web of Science ®Google Scholar
• Javidfar J, Speicher PJ, Hartwig MG, et al. Impact of positive margins on survival in patients undergoing esophagogastrectomy for esophageal cancer. Ann Thorac Surg. 2016;101(3):1060–1067.
   PubMed Web of Science ®Google Scholar
• Gertler R, Richter J, Stecher L, et al. What to do after R1-resection of adenocarcinomas of the esophagogastric junction? J Surg Oncol. 2016;114(4):428–433.
   PubMed Web of Science ®Google Scholar